Program
Interferon beta-1a
Also written as “Rebif®”, “RNF” and “Rebif”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 230 open or running | phase 4since Sep 13, 2005 | Dec 15, 2004 | none ahead |
| Merck KGaA, Darmstadt, Germany | 210 open or running | phase 4since Feb 23, 2004 | Feb 23, 2004 | none ahead |
| Faron Pharmaceuticals | 30 open or running | phase 3since Nov 24, 2015 | Nov 24, 2015 | none ahead |
| Biocad | 20 open or running | phase 3since May 29, 2015 | Jan 10, 2013 | none ahead |
| Cinnagen | 20 open or running | phase 3since Jan 17, 2022 | Jul 14, 2018 | none ahead |
| Azidus Brasil | 10 open or running | phase 1since Nov 13, 2009 | Nov 13, 2009 | none ahead |
| Trio Medicines | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Feb 23, 2004.
- Jan 10, 2013Biocad’s first study: phase 1 study in HealthyNew to BiocadBiocad · NCT01766024 · 32 enrolled · Russian Federation
- Feb 12, 2013Phase 4 study in Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT01791244 · 93 enrolled · Germany, Sweden
- May 20, 2013Trio Medicines’ first study: phase 1 study in Multiple SclerosisNew to Trio MedicinesTrio Medicines · NCT01863069 · 77 enrolled · United Kingdom
- Feb 13, 2014Phase 4 study in Multiple Sclerosis, Relapsing-RemittingMerck KGaA, Darmstadt, Germany · NCT02064816 · 200 enrolled · Germany
- Apr 15, 2014Phase 4 study in Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT02117050 · 1 enrolled · United States
- Sep 29, 2014Phase 4 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT02254304 · 106 enrolled · Germany
- Oct 17, 2014Phase 1 study in Multiple SclerosisBiogen · NCT02269930 · 30 enrolled · United States
- May 29, 2015Phase 3 study in Multiple SclerosisBiocad · NCT02727907 · 163 enrolled · Russian Federation
- Nov 24, 2015Faron Pharmaceuticals’ first study: phase 3 study in Respiratory Distress SyndromeNew to Faron PharmaceuticalsFaron Pharmaceuticals · NCT02622724 · 301 enrolled · Belgium, Czechia, Finland and more
- Jan 26, 2017Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT03177083 · 80 enrolled · Portugal
- Mar 3, 2017Phase 2 study in Multiple Organ FailureFaron Pharmaceuticals · NCT03119701 · 40 enrolled · Estonia, Finland, Lithuania
- Jul 14, 2018Cinnagen’s first study: phase 1 study in BioequivalenceNew to CinnagenCinnagen · NCT03614715 · 40 enrolled · Finland
- Apr 22, 2021Phase 2 study in COVID-19Faron Pharmaceuticals · NCT04860518 · 7 enrolled · United States
- Jan 17, 2022Phase 3 study in Multiple Sclerosis, Relapsing-RemittingCinnagen · NCT05242133 · 168 enrolled · Iran, Islamic Republic of
TargetBeta
“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05242133Multiple Sclerosis, Relapsing-Remitting · Iran, Islamic Republic of | 3 | Completed | Cinnagen | Apr 27, 2022 | 168 |
| NCT04860518COVID-19 · United States | 2 | Terminated | Faron Pharmaceuticals | Apr 4, 2022 | 7 |
| NCT03614715Bioequivalence · Finland | 1 | Completed | Cinnagen | Feb 12, 2019 | 40 |
| NCT03119701Multiple Organ Failure · Estonia, Finland, Lithuania | 2 | Terminated | Faron Pharmaceuticals | Sep 23, 2019 | 40 |
| NCT03177083Multiple Sclerosis, Relapsing-Remitting · Portugal | 4 | Completed | Biogen | Oct 26, 2020 | 80 |
| NCT02622724Respiratory Distress Syndrome · Belgium, Czechia, Finland and more | 3 | Terminated | Faron Pharmaceuticals | May 17, 2018 | 301 |
| NCT02727907Multiple Sclerosis · Russian Federation | 3 | Completed | Biocad | Nov 21, 2016 | 163 |
| NCT02269930Multiple Sclerosis · United States | 1 | Completed | Biogen | Dec 2014 | 30 |
| NCT02254304Relapsing Multiple Sclerosis · Germany | 4 | Completed | Merck KGaA, Darmstadt, Germany | Aug 20, 2016 | 106 |
| NCT02117050Multiple Sclerosis · United States | 4 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 2015 | 1 |
| NCT02064816Multiple Sclerosis, Relapsing-Remitting · Germany | 4 | Completed | Merck KGaA, Darmstadt, Germany | Apr 30, 2016 | 200 |
| NCT01863069Multiple Sclerosis · United Kingdom | 1 | Completed | Trio Medicines | Oct 2001 | 77 |
| NCT01791244Multiple Sclerosis · Germany, Sweden | 4 | Completed | Merck KGaA, Darmstadt, Germany | Feb 29, 2016 | 93 |
| NCT01766024Healthy · Russian Federation | 1 | Completed | Biocad | Jun 2013 | 32 |
| NCT01500408Multiple Sclerosis · United States | 1 | Completed | Biogen | Apr 2012 | 110 |
| NCT01416207Healthy · China | 1 | Completed | Biogen | Oct 2011 | 24 |
| NCT01285401Multiple Sclerosis, Relapsing-Remitting · Austria, Denmark, Estonia and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2015 | 260 |
| NCT01201343Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jul 2010 | 79 |
| NCT01181115Multiple Sclerosis · China | 3 | Completed | Biogen | Oct 2011 | 60 |
| NCT01142466Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Merck KGaA, Darmstadt, Germany | Dec 2009 | 30 |
| NCT01119677Healthy Volunteers · United States | 1 | Completed | Biogen | Oct 23, 2010 | 120 |
| NCT01085318Multiple Sclerosis · United States | 4 | Completed | Merck KGaA, Darmstadt, Germany | Feb 29, 2012 | 38 |
| NCT01075763Alzheimer Disease · Italy | 2 | Completed | Merck KGaA, Darmstadt, Germany | May 2008 | 42 |
| NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain | 2 | Completed | Biogen | Nov 2011 | 175 |
| NCT01074593Healthy · Brazil | 1 | Completed | Azidus Brasil | Mar 2011 | 20 |
| NCT00915577Multiple Sclerosis | 3 | Completed | Biogen | Apr 2006 | 74 |
| NCT00915460Multiple Sclerosis | 4 | Completed | Biogen | Jun 2003 | 408 |
| NCT00913666Multiple Sclerosis | 4 | Completed | Biogen | 121 | |
| NCT00913250Multiple Sclerosis | 1 | Completed | Biogen | 96 | |
| NCT00912860Multiple Sclerosis | 2 | Completed | Biogen | Dec 2004 | 155 |
| NCT00828204Multiple Sclerosis · United States | 3 | Completed | Biogen | Jul 2010 | 95 |
| NCT00813709Multiple Sclerosis · Argentina, Austria, Belgium and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2011 | 402 |
| NCT00784836Multiple Sclerosis · United States | 3 | Terminated | Biogen | Feb 2009 | 3 |
| NCT00771043Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Biogen | Aug 1, 2009 | 0 |
| NCT00725985Multiple Sclerosis · United States, Argentina, Austria and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jul 31, 2011 | 617 |
| NCT00616434Active Ulcerative Colitis · United States, Canada, Czech Republic and more | 2 | Completed | Biogen | Mar 2010 | 123 |
| NCT00574041Multiple Sclerosis, Relapsing-Remitting · Australia | 4 | Terminated | Biogen | Feb 2008 | 19 |
| NCT00534261Multiple Sclerosis, Relapsing-Remitting · Belgium, Luxembourg, United Kingdom | 4 | Completed | Biogen | 284 | |
| NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand | 4 | Completed | Biogen | Dec 2009 | 20 |
| NCT00493077Multiple Sclerosis · Sweden | 4 | Completed | Biogen | May 2006 | 3 |
| NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland | 4 | Completed | Biogen | Aug 2006 | 14 |
| NCT00441103Multiple Sclerosis, Relapsing-Remitting | 3 | Completed | Merck KGaA, Darmstadt, Germany | Nov 2008 | 180 |
| NCT00404352Multiple Sclerosis · Argentina, Australia, Austria and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2010 | 517 |
| NCT00367484Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2006 | 460 |
| NCT00304252Crohn Disease · Germany, Italy, Sweden and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | 192 | |
| NCT00303381Colitis, Ulcerative · Germany, Israel, Netherlands and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2003 | 194 |
| NCT00292266Multiple Sclerosis, Relapsing-Remitting | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jun 2002 | 677 |
| NCT00287079Clinically Isolated Syndrome · Canada | 3 | Completed | Merck KGaA, Darmstadt, Germany | Nov 2008 | 35 |
| NCT00249860Hepatitis C | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2005 | 257 |
| NCT00168766Multiple Sclerosis, Relapsing-Remitting · Belgium, Denmark, Finland and more | 4 | Completed | Biogen | Nov 2008 | 345 |
| NCT00101959Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Merck KGaA, Darmstadt, Germany | 0 | |
| NCT00099489Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more | 2 | Completed | Biogen | Feb 2006 | 67 |
| NCT00078338Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Austria and more | 4 | Completed | Merck KGaA, Darmstadt, Germany | Nov 28, 2006 | 764 |
How it is read
Names in the registry
- “Interferon beta-1a”, 11 entries
- “Rebif®”, 7 entries
- “RNF”, 5 entries
- “Rebif”, 4 entries
- “SNG001”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 21 studies
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- COVID-19, 3 studies
- Colitis, Ulcerative, 2 studies
- Pneumonia, Viral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.